特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
949448

喘息・COPD治療薬の世界市場:2020-2026年

Global Asthma and COPD Drugs Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.37円
喘息・COPD治療薬の世界市場:2020-2026年
出版日: 2020年05月21日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の喘息・COPD治療薬市場は、予測期間中、大幅なCAGRで成長すると予測されています。市場の成長は、喘息・COPD患者数の増加、および喘息・COPD治療薬の臨床試験の増加に起因しています。人々のライフスタイルの変化は、呼吸器疾患の主な原因となっています。喫煙、飲酒、不健康な摂食行動が人々の間で増加しており、これは様々な呼吸器関連疾患の発症の主要なリスクとなっています。米国のCOPD財団によると、COPDの原因となるトップ3は、環境要因、喫煙、遺伝的要因です。 COPDは主に40歳以上で喫煙歴のある人に発生します。米国のCOPD患者の約90%は喫煙歴があります。

当レポートでは、世界の喘息・COPD治療薬市場について調査分析し、市場概要、市場成長への影響要因、市場規模と予測、セグメント別の市場分析、地域・国別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要および考察

  • 調査範囲
  • アナリストの考察&現在の市場動向
  • 規則&規制

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Grifols, S.A.
    • GlaxoSmithKline PLC
    • Pfizer Inc.

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の喘息・COPD治療薬市場:タイプ別
    • 喘息
    • COPD
  • 世界の喘息・COPD治療薬市場:薬剤クラス別
    • 抗炎症薬
    • 併用薬
    • モノクローナル抗体
    • 気管支拡張薬

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • その他の地域

第7章 企業プロファイル

  • Amgen Inc.
  • AptarGroup, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Glenmark Pharmaceuticals
  • Merck & Co., Inc.
  • MediciNova, Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Respiratorius AB
  • Teva Pharmaceutical Industries Ltd.
  • Vectura Group plc
  • Verona Pharma plc
図表

LIST OF TABLES

  • 1. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL ASTHMA DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL COPD DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)

4. G

  • 5. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 6. GLOBAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL COMBINATION DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL MONOCLONAL ANTIBODIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL BRONCHODILATORS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 14. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 16. EUROPEAN ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 20. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY DISEASE TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
  • 3. GLOBAL ASTHMA AND COPD DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD ASTHMA AND COPD DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2021767

Global Asthma and COPD Drugs Market Size, Share & Trends Analysis Report by Disease Type(Asthma and COPD), By Application (Cardiology, Orthopedics, General Surgery &Anesthesia, Neurology Urology, Others) and Forecast 2020-2026

The global asthma and COPD drugs market is estimated to grow significantly during the forecast period. The growth of the market is attributed to the increasing number of patients with asthma and COPD coupled with growing clinical trials on asthma and COPD drugs. Changing lifestyle of the people is a major cause of respiratory diseases among people. Trend of smoking, drinking alcohol and ill eating activity are increasing among the people which is a major risk for the development of various respiratory related diseases. As per COPD Foundation of the US, top three causes of COPD are environmental factor, smoking and genetic factor. COPD is mostly occurred in the people of age above 40 and having a history of smoking. About 90% of the COPD patients in the US have smoking history. Therefore lifestyle changes further increases the number of cases of respiratory diseases that further contribute in the market growth.

The global asthma and COPD drugs market is segmented on the basis of disease type and drug class. Based on the disease type, the market is further classified into asthma and COPD. The asthma segment is projected to have a considerable share in the global market owing to the high number of cases of asthma across the globe. Based on the drug class, the global asthma and COPD drugs market is further segmented into anti-inflammatory drugs, combination drugs, monoclonal antibodies, bronchodilators. Based on geography, the global asthma and COPD drugs market is further segregated into North America, Europe, Asia-Pacific and the Rest of the World. Among, region North America projected to have a considerable share in the global asthma and COPD drugs market.

The companies which are contributing to the growth of the global asthma and COPD drugs market include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Grifols, S.A., GlaxoSmithKline PLC, Pfizer Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.

Research Methodology

The market study of the global asthma and COPD drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for asthma and COPD drugs providers, end-user companies for overall market analysis, and competitive analysis. The report provides an in-depth analysis of pricing, market size, intended quality of the product preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.

Market Segmentation

1. Global asthma and COPD drugs Market Research and Analysis by Disease Type

2. Global asthma and COPD drugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global asthma and COPD drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global asthma and COPD drugs market.
  • Insights about market determinants which are stimulating the global asthma and COPD drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Boehringer Ingelheim International GmbH
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Grifols, S.A.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. GlaxoSmithKline PLC
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Pfizer Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Asthma and COPD Drugs Market by Disease Type
    • 5.1.1. Asthma
    • 5.1.2. COPD
  • 5.2. Global Asthma and COPD Drugs Market by Drug class
    • 5.2.1. Anti-inflammatory Drugs
    • 5.2.2. Combination Drugs
    • 5.2.3. Monoclonal Antibodies
    • 5.2.4. Bronchodilators

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Amgen Inc.
  • 7.2. AptarGroup, Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Boehringer Ingelheim International GmbH
  • 7.5. Cipla Ltd.
  • 7.6. F. Hoffmann-La Roche Ltd.
  • 7.7. GlaxoSmithKline PLC
  • 7.8. Grifols, S.A.
  • 7.9. Glenmark Pharmaceuticals
  • 7.10. Merck & Co., Inc.
  • 7.11. MediciNova, Inc.
  • 7.12. Mylan N.V.
  • 7.13. Novartis AG
  • 7.14. Pfizer Inc.
  • 7.15. Respiratorius AB
  • 7.16. Teva Pharmaceutical Industries Ltd.
  • 7.17. Vectura Group plc
  • 7.18. Verona Pharma plc
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.